The state of Colorado currently has 4 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. These trials are conducted in various cities, including Denver, Aurora, Colorado Springs and Englewood.
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Recruiting
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Centennial, Colorado +1 locations
Conditions: Hereditary Angioedema
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Centennial, Colorado +1 locations
Conditions: Hereditary Angioedema
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/16/2024
Locations: Ionis Investigative Site, Colorado Springs, Colorado
Conditions: Hereditary Angioedema
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
Recruiting
This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficienc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Asthma & Allergy Associates P.C., Colorado Springs, Colorado
Conditions: Hereditary Angioedema, HAE